RXi Pharmaceuticals (NASDAQ:RXII) shares rose 0.3% during mid-day trading on Thursday . The stock traded as high as $5.16 and last traded at $3.30. Approximately 222,331 shares changed hands during mid-day trading, a decline of 22% from the average daily volume of 285,286 shares. The stock had previously closed at $3.31.
Separately, ValuEngine raised RXi Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd.
The stock has a market cap of $8.94, a price-to-earnings ratio of -0.75 and a beta of 1.13.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings data on Monday, March 26th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.12. The company had revenue of $0.02 million for the quarter. During the same period in the previous year, the business posted ($6.02) earnings per share. equities research analysts anticipate that RXi Pharmaceuticals will post -3.44 EPS for the current year.
WARNING: “RXi Pharmaceuticals (RXII) Stock Price Up -0.3%” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/rxi-pharmaceuticals-rxii-stock-price-up-0-3.html.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. It develops therapies based on its self-delivering RNAi (sd-rxRNA) platform; and Samcyprone topical immunomodulatory. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.